RT Journal Article
SR Electronic
T1 Adeno-associated virus 2 infection in children with non-A-E hepatitis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.19.22277425
DO 10.1101/2022.07.19.22277425
A1 Ho, Antonia
A1 Orton, Richard
A1 Tayler, Rachel
A1 Asamaphan, Patawee
A1 Tong, Lily
A1 Smollett, Katherine
A1 Davis, Chris
A1 Manali, Maria
A1 McDonald, Sarah E.
A1 Pollock, Louisa
A1 Evans, Clair
A1 McMenamin, Jim
A1 Roy, Kirsty
A1 Marsh, Kimberly
A1 Divala, Titus
A1 Holden, Matt
A1 Lockhart, Michael
A1 Yirrell, David
A1 Currie, Sandra
A1 Shepherd, Samantha J.
A1 Jackson, Celia
A1 Gunson, Rory
A1 MacLean, Alasdair
A1 McInnes, Neil
A1 Battle, Richard
A1 Hollenbach, Jill
A1 Henderson, Paul
A1 Chand, Meera
A1 Hamilton, Melissa Shea
A1 Estrada-Rivadeneyra, Diego
A1 Levin, Michael
A1 DIAMONDS consortium
A1 ISARIC4C Investigators
A1 Robertson, David L
A1 Filipe, Ana
A1 Willett, Brian
A1 Breuer, Judith
A1 Semple, Malcolm G
A1 Turner, David
A1 Baillie, J Kenneth
A1 Thomson, Emma C.
YR 2022
UL http://medrxiv.org/content/early/2022/07/19/2022.07.19.22277425.abstract
AB An outbreak of acute hepatitis of unknown aetiology in children was first reported in Scotland in April 2022.1 Cases aged <16 years have since been identified in 35 countries.2 Here we report a detailed investigation of 9 early cases and 58 control subjects. Using next-generation sequencing and real-time PCR, adeno-associated virus 2 (AAV2), was detected in the plasma of 9/9 and liver of 4/4 patients but in 0/13 sera/plasma of age-matched healthy controls, 0/12 children with adenovirus (HAdV) infection and normal liver function and 0/33 children admitted to hospital with hepatitis of other aetiology. AAV2 typically requires a coinfecting ‘helper’ virus to replicate, usually HAdV or a herpesvirus. HAdV (species C and F) and human herpesvirus 6B (HHV6B) were detected in 6/9 and 3/9 affected cases, including 3/4 and 2/4 liver biopsies, respectively. The class II HLA-DRB1*04:01 allele was identified in 8/9 cases (89%), compared with a background frequency of 15.6% in Scottish blood donors, suggestive of increased susceptibility in affected cases. Acute non-A-E paediatric hepatitis is associated with the presence of AAV2 infection, which could represent a primary pathogen or a useful biomarker of recent HAdV or HHV6B infection. Population and mechanistic studies are required to explore these findings further.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was funded by Public Health Scotland and the National Institute for Health Research (NIHR award COCIN01) and the Medical Research Council (MRC grants MC_UU_1201412, MC_PC_19059 & MC_PC_22004). DIAMONDS is funded by the European Union Horizon 2020 programme grant 848196).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All patients (cases and controls) were recruited with the informed written consent of parents or guardians. Ethical approval was given for the recruitment of cases by the South Central Oxford C Research Ethics Committee in England (13/SC/0149), the Scotland A Research Ethics Committee (20/SS/0028), and the WHO Ethics Review Committee (RPC571 and RPC572) for the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCPUK). Control samples were obtained from the Diagnosis and Management of Febrile Illness using RNA Personalised Molecular Signature Diagnosis study cohort (DIAMONDS). The DIAMONDS study was approved by the London Dulwich Research Ethics Committee (20/HRA/1714). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors, other than patient-specific data that cannot be released for reasons of confidentiality under the relevant ethical approvals.